CO6180501A2 - Formulaciones y composiciones farmaceuticas de un antagonist selectivo del cxcr2 o cxcr1 o ambos cxcr1 y cxcr2 y metodos de utilizacion de los mismos para tratar trastornos inflamatorios - Google Patents
Formulaciones y composiciones farmaceuticas de un antagonist selectivo del cxcr2 o cxcr1 o ambos cxcr1 y cxcr2 y metodos de utilizacion de los mismos para tratar trastornos inflamatoriosInfo
- Publication number
- CO6180501A2 CO6180501A2 CO09002100A CO09002100A CO6180501A2 CO 6180501 A2 CO6180501 A2 CO 6180501A2 CO 09002100 A CO09002100 A CO 09002100A CO 09002100 A CO09002100 A CO 09002100A CO 6180501 A2 CO6180501 A2 CO 6180501A2
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- cxcr1
- cxcr2
- pharmaceutically acceptable
- wetting agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
1.- Una composición que comprende el Compuesto I o una sal farmacéuticamente aceptable del mismo y al menos un excipiente farmacéuticamente aceptable el cual proporciona liberación de por lo menos 83% del Compuesto I en 5 minutos cuando se prueba utilizando un aparato Agitador de Paleta USPII llenado con 900 mL de medio de disolución el cual consta de solución de lauril sulfato de sodio al 0.5% amortiguado con amortiguador de fosfato de sodio a pH de 6.8 a 37°C ± 0.5°C con la velocidad de paleta fijada en 75 RPM. 2.- La composición de la Reivindicación 1, la cual proporciona liberación de por lo menos 99% del Compuesto I en 15 minutos. 3.- La composición de la Reivindicación 1, en donde al menos un excipiente farmacéuticamente aceptable es uno o más agentes humectantes, uno o más aglomerantes, uno o más diluyentes, o uno o más desintegrantes. 4.- La composición de la Reivindicación 1, en donde al menos un excipiente farmacéuticamente aceptable es uno o más agentes humectantes, uno o más aglomerantes, no o más diluyentes, y uno o más desintegrantes. 5.- La composición de la Reivindicación 1, en donde la composición tiene color estable como se evaluó al comparar el color de una primera muestra tomada después de mezclar el Compuesto I, uno o más agentes humectantes, uno o más aglomerantes, uno o más diluyentes, o uno o más desintegrantes en un lecho fluido con una segunda muestra tomada después de una pérdida al secar < 4% logrado bajo una temperatura de aire de entrada de 70°C, y la segunda muestra continua secándose bajo la temperatura de aire de entrada de 70°C durante por lo menos 80 minutos. 6.- La composición de la Reivindicación 3, en donde uno o más agentes humectantes están presentes entre 0.1 y 8% aproximadamente por peso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81272406P | 2006-06-12 | 2006-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6180501A2 true CO6180501A2 (es) | 2010-07-19 |
Family
ID=38626405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09002100A CO6180501A2 (es) | 2006-06-12 | 2009-01-13 | Formulaciones y composiciones farmaceuticas de un antagonist selectivo del cxcr2 o cxcr1 o ambos cxcr1 y cxcr2 y metodos de utilizacion de los mismos para tratar trastornos inflamatorios |
Country Status (18)
Country | Link |
---|---|
US (1) | US8183287B2 (es) |
EP (1) | EP2026770A1 (es) |
JP (1) | JP2009539990A (es) |
KR (1) | KR20090024248A (es) |
CN (1) | CN101500544B (es) |
AR (1) | AR061448A1 (es) |
AU (1) | AU2007258325B2 (es) |
BR (1) | BRPI0713647A2 (es) |
CA (1) | CA2654990A1 (es) |
CL (1) | CL2007001714A1 (es) |
CO (1) | CO6180501A2 (es) |
MX (1) | MX2008016016A (es) |
NO (1) | NO20090145L (es) |
NZ (1) | NZ573566A (es) |
PE (1) | PE20080368A1 (es) |
TW (1) | TWI351399B (es) |
WO (1) | WO2007146296A1 (es) |
ZA (1) | ZA200810760B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3011012B1 (en) | 2013-06-18 | 2018-09-12 | New York University | Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets |
JP6702883B2 (ja) * | 2014-04-25 | 2020-06-03 | ノーレックス インコーポレイテッド | 向神経活性ペプチドの安定な組成物 |
WO2022155507A1 (en) * | 2021-01-15 | 2022-07-21 | Jubilant Pharma Holdings Inc. | Transmucosal dosage forms of brexanolone |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
GB9511694D0 (en) * | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
ATE365154T1 (de) * | 2001-04-16 | 2007-07-15 | Schering Corp | 3,4-disubstituierte cyclobuten-1,2-dione als cxc- chemokinrezeptorliganden |
US7132445B2 (en) * | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
CN1522140A (zh) * | 2001-05-18 | 2004-08-18 | 兰贝克赛实验室有限公司 | 奥卡西平剂型 |
JP2005512990A (ja) * | 2001-11-07 | 2005-05-12 | ファルマシア・コーポレーション | 流動層造粒法により製造される口腔内崩壊型バルデコキシブ組成物 |
KR20040083478A (ko) * | 2002-01-07 | 2004-10-02 | 파마시아 코포레이션 | 시클로옥시게나제-2 선택성 억제제 및 아스피린의조합물을 이용한 통증, 염증 및 염증-관련 장애의 치료 |
BR0308739A (pt) * | 2002-03-18 | 2005-01-11 | Schering Corp | Tratamentos em combinação para doenças mediadas por quimiocina |
AR044027A1 (es) | 2003-04-18 | 2005-08-24 | Schering Corp | Sintesis de 2-hidroxi-n,n-dimetil-3-[[2-[1(r) - (5-metil-2-furanil)propil]amino]- 3,4-dioxo-1-ciclobuten-1-il]amino]benzamida |
DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
JP2007519751A (ja) | 2004-01-30 | 2007-07-19 | シェーリング コーポレイション | Cxc−ケモカインレセプターリガンドの結晶多形 |
-
2007
- 2007-06-12 AR ARP070102568A patent/AR061448A1/es not_active Application Discontinuation
- 2007-06-12 EP EP07809491A patent/EP2026770A1/en not_active Withdrawn
- 2007-06-12 JP JP2009515461A patent/JP2009539990A/ja active Pending
- 2007-06-12 CN CN2007800295171A patent/CN101500544B/zh not_active Expired - Fee Related
- 2007-06-12 MX MX2008016016A patent/MX2008016016A/es not_active Application Discontinuation
- 2007-06-12 CL CL2007001714A patent/CL2007001714A1/es unknown
- 2007-06-12 US US11/761,588 patent/US8183287B2/en active Active
- 2007-06-12 BR BRPI0713647-1A patent/BRPI0713647A2/pt not_active IP Right Cessation
- 2007-06-12 WO PCT/US2007/013805 patent/WO2007146296A1/en active Application Filing
- 2007-06-12 NZ NZ573566A patent/NZ573566A/en not_active IP Right Cessation
- 2007-06-12 AU AU2007258325A patent/AU2007258325B2/en not_active Ceased
- 2007-06-12 KR KR1020097000469A patent/KR20090024248A/ko not_active Application Discontinuation
- 2007-06-12 CA CA002654990A patent/CA2654990A1/en not_active Abandoned
- 2007-06-12 TW TW096121180A patent/TWI351399B/zh not_active IP Right Cessation
- 2007-06-12 PE PE2007000740A patent/PE20080368A1/es not_active Application Discontinuation
-
2008
- 2008-12-19 ZA ZA2008/10760A patent/ZA200810760B/en unknown
-
2009
- 2009-01-09 NO NO20090145A patent/NO20090145L/no not_active Application Discontinuation
- 2009-01-13 CO CO09002100A patent/CO6180501A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US8183287B2 (en) | 2012-05-22 |
KR20090024248A (ko) | 2009-03-06 |
TW200811123A (en) | 2008-03-01 |
AU2007258325A1 (en) | 2007-12-21 |
CN101500544A (zh) | 2009-08-05 |
AU2007258325B2 (en) | 2013-02-21 |
EP2026770A1 (en) | 2009-02-25 |
TWI351399B (en) | 2011-11-01 |
MX2008016016A (es) | 2009-02-25 |
PE20080368A1 (es) | 2008-05-16 |
CL2007001714A1 (es) | 2008-01-18 |
NZ573566A (en) | 2012-01-12 |
CA2654990A1 (en) | 2007-12-21 |
BRPI0713647A2 (pt) | 2012-10-23 |
WO2007146296A1 (en) | 2007-12-21 |
AR061448A1 (es) | 2008-08-27 |
NO20090145L (no) | 2009-03-11 |
US20080021100A1 (en) | 2008-01-24 |
CN101500544B (zh) | 2012-08-08 |
JP2009539990A (ja) | 2009-11-19 |
ZA200810760B (en) | 2013-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP109917A (es) | Nuevos derivados de ácido azabifenilaminobenzoico | |
AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
EA201070186A1 (ru) | Способы и соединения, предназначенные для получения ингибиторов котранспортера натрий-глюкозы 2 типа | |
GT200600518A (es) | Derivados de pirimidina | |
ECSP066541A (es) | Nuevos derivados de piridazin-3(2h)-ona | |
EA201100030A1 (ru) | Пиразольные соединения 436 | |
AR066492A1 (es) | Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres. | |
EA201071329A1 (ru) | Диамидные производные адамантана и их применение | |
PE20221914A1 (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido | |
AR078535A1 (es) | Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras | |
EA201001368A1 (ru) | Гетероциклические производные мочевины и способы их применения-211 | |
AR092045A1 (es) | Combinaciones farmaceuticas | |
AR041250A1 (es) | Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa | |
CL2004000918A1 (es) | Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria | |
ATE507212T1 (de) | Morpholine als 5ht2c-agonisten | |
CL2011002859A1 (es) | Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c. | |
CU20090072A7 (es) | Ácido l-glutámico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, así como procedimientos para su preparación | |
EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
AR056645A1 (es) | Compuestos de urea sustituida inhibidores de enzimas chk1 . | |
BR112014009910A2 (pt) | formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico | |
CO6180501A2 (es) | Formulaciones y composiciones farmaceuticas de un antagonist selectivo del cxcr2 o cxcr1 o ambos cxcr1 y cxcr2 y metodos de utilizacion de los mismos para tratar trastornos inflamatorios | |
AR080253A1 (es) | Inhibidores dimericos de las iap (proteinas inhibidoras de la apoptosis) | |
AR079967A1 (es) | Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos | |
ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
EA201001858A1 (ru) | Гетероциклические производные мочевины для лечения бактериальных инфекций |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |